High sensitivity C reactive protein level is associated with prognosis in patients with severe coronavirus disease 19 pneumonia

Lei Zhang¹, Bilian Yu², Lizhen Yang³, Hong Zhang⁴, Guxiang Huang⁵, Liang Tang², Min Xu⁶, Jienan Zhou⁷, Le Xiao⁷, Jianjun Tang², Xianling Liu⁸, Chang Shu⁹, Xin Li^10
1 Department of Vascular Surgery, Secondary Xiangya Hospital, Central South University; Vascular Diseases Institute, Changsha, Hunan, China
² Department of cardiovascular medicine, Secondary Xiangya Hospital, Central South University, Changsha; Anti-2019-nCov pneumonia medical support group to Wuhan from Secondary Xiangya Hospital, Central South University at Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei, China
³ Anti-2019-nCov pneumonia medical support group to Wuhan from Secondary Xiangya Hospital, Central South University at Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei; Respiratory intensive care unit, Secondary Xiangya Hospital, Central South University, Changsha, China
⁴ Anti-2019-nCov pneumonia medical support group to Wuhan from Secondary Xiangya Hospital, Central South University at Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei; Department of Cardiac surgery, Secondary Xiangya Hospital, Central South University, Changsha, China
⁵ Anti-2019-nCov pneumonia medical support group to Wuhan from Secondary Xiangya Hospital, Central South University at Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei; Department of Geratology, Secondary Xiangya Hospital, Central South University, Changsha, China
⁶ Anti-2019-nCov pneumonia medical support group to Wuhan from Secondary Xiangya Hospital, Central South University at Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei; Intensive care unit, Secondary Xiangya Hospital, Central South University, Changsha, China
⁷ Department of Vascular Surgery, Secondary Xiangya Hospital, Central South University; Vascular Diseases Institute, Changsha, Hunan; Anti-2019-nCov pneumonia medical support group to Wuhan from Secondary Xiangya Hospital, Central South University at Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei, China
⁸ Anti-2019-nCov pneumonia medical support group to Wuhan from Secondary Xiangya Hospital, Central South University at Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei; Department of Oncology, Secondary Xiangya Hospital, Central South University, Changsha, China
⁹ Department of Vascular Surgery, Secondary Xiangya Hospital, Central South University; Vascular Diseases Institute, Changsha, Hunan; State key laboratory of cardiovascular diseases, Central of vascular surgery, Fuwai Hospital, National Centre for Cardiovascular disease, Chinese academic of Medical Sciences and Peking Union Medical College, Beijing, China
¹⁰ Department of Vascular Surgery, Secondary Xiangya Hospital, Central South University; Vascular Diseases Institute, No.139 Renmin Road-Changsha -410011, Hunan; Anti-2019-nCov pneumonia medical support group to Wuhan from Secondary Xiangya Hospital, Central South University at Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei, China

Correspondence Address:
Dr. Xin Li
Department of Vascular Surgery, Secondary Xiangya Hospital, Central South University, No.139 Renmin Road-Changsha-410011, Hunan, China. Vascular Diseases Institute, Central South University, Changsha, Hunan, China. Anti-2019-nCov Pneumonia Medical Support Group to Wuhan from Secondary Xiangya Hospital, Central South University at Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei
China

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/2589-9686.32192